Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check37 days agoChange DetectedDifference0.4%
- Check45 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check52 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check66 days agoChange DetectedThe website has been updated with new entries for January 2025, including a new revision (v2.14.1), while previous updates from December 2024 have been removed.SummaryDifference0.7%
- Check73 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.